Clinical and Population Health Research Program, Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA, USA.
Division of Epidemiology, Department of Population and Quantitative Health Services, University of Massachusetts Medical School, Worcester, MA, USA.
J Clin Pharm Ther. 2021 Dec;46(6):1714-1728. doi: 10.1111/jcpt.13508. Epub 2021 Aug 31.
Anticoagulants are indicated for treatment and prevention of several clinical conditions. Prior studies have examined anticoagulant utilization for specific indications and in community-dwelling populations. Decision-making regarding anticoagulant prescribing in the nursing home setting is particularly challenging because advanced age and clinical complexity places most residents at increased risk for adverse drug events. To estimate the prevalence of oral anticoagulant (OAC) use (overall, warfarin, direct oral anticoagulants (DOACs)) and identify factors associated with oral anticoagulant use among the general population of residents living in nursing homes.
This point prevalence study was conducted among 506,482 residents in US nursing homes on 31 October 2016 who were enrolled in Medicare fee-for-service. Covariates including demographics, clinical conditions, medications, cognitive impairment and functional status were obtained from Minimum Data Set 3.0 assessments and Medicare Part A and D claims. Oral anticoagulant use was identified using dispensing dates and days supply information from Medicare Part D claims. Robust Poisson models estimated adjusted prevalence ratios (aPR) for associations between covariates and 1) any anticoagulant use, and 2) DOAC versus warfarin use.
Overall, 11.8% of residents used oral anticoagulants. Among users, 44.3% used DOACs. Residents with body mass index (BMI) ≥40 kg/m (aPR: 1.66; 95% CI: 1.61 -1.71), with functional dependency in activities of daily living, polypharmacy and higher CHA DS -VASc risk ischaemic stroke scores, had a higher prevalence of oral anticoagulant use. Women (aPR: 0.78; 95% CI: 0.76-0.79), residents with limited life expectancy (aPR 0.80; 95% CI: 0.76-0.83), those with moderate-to-severe cognitive impairment (aPR: 0.67; 95% CI: 0.65-0.68), those using NSAIDs or antiplatelets, and non-white racial/ethnic groups had a lower prevalence of anticoagulant use. Residents with higher levels of polypharmacy, BMI and age had a lower prevalence of DOAC use (versus warfarin).
Approximately one in eight general nursing home residents use oral anticoagulants and among oral anticoagulant users, only slightly more residents used warfarin than DOACs. The lower prevalence of anticoagulation among women and non-white racial/ethnic groups raises concerns of potential inequities in quality of care. Lower oral anticoagulant use among residents with limited life expectancy suggests possible deprescribing at the end of life. Further research is needed to inform resident-centred shared decision-making that explicitly considers treatment goals and individual-specific risks and benefits of anticoagulation at all stages of the medication use continuum.
抗凝剂用于治疗和预防多种临床病症。先前的研究已经检查了特定病症和社区居住人群中抗凝剂的使用情况。在养老院环境中决定抗凝剂的处方特别具有挑战性,因为高龄和临床复杂性使大多数居民面临发生药物不良事件的风险增加。本研究旨在评估口服抗凝剂(OAC)(总体、华法林、直接口服抗凝剂(DOAC))的使用情况,并确定与一般居住在养老院的居民中 OAC 使用相关的因素。
本研究采用 2016 年 10 月 31 日美国养老院中 506482 名参加医疗保险费服务的居民进行了点患病率研究。从最低数据集 3.0 评估和医疗保险 A 部分和 D 部分索赔中获得了包括人口统计学、临床状况、药物、认知障碍和功能状态在内的协变量。使用医疗保险 D 部分索赔中的配药日期和供应天数信息来确定口服抗凝剂的使用情况。使用稳健泊松模型估计了协变量与 1)任何抗凝剂使用和 2)DOAC 与华法林使用之间的调整后患病率比(aPR)。
总体而言,有 11.8%的居民使用了口服抗凝剂。在使用者中,有 44.3%使用了 DOAC。体重指数(BMI)≥40kg/m(aPR:1.66;95%CI:1.61-1.71)、日常生活活动功能依赖、多药治疗和更高的 CHA2DS2-VASc 缺血性中风风险评分的居民,其口服抗凝剂使用率更高。女性(aPR:0.78;95%CI:0.76-0.79)、预期寿命有限的居民(aPR:0.80;95%CI:0.76-0.83)、中重度认知障碍的居民(aPR:0.67;95%CI:0.65-0.68)、使用 NSAIDs 或抗血小板药物以及非白种人群的抗凝剂使用率较低。多药治疗、BMI 和年龄较高的居民使用 DOAC 的比例较低(与华法林相比)。
大约每八名普通养老院居民中就有一名使用口服抗凝剂,在口服抗凝剂使用者中,使用华法林的患者略多于 DOAC。女性和非白种人群中抗凝治疗的比例较低,这表明在护理质量方面可能存在潜在的不平等。预期寿命有限的居民中口服抗凝剂使用率较低,提示可能在生命结束时进行药物停用。需要进一步研究,以便在药物使用连续体的所有阶段,为居民提供以患者为中心的共同决策,明确考虑治疗目标和个体的具体风险和抗凝益处。